Overview

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cancer cell growth. Studying samples of blood and tissue from patients with breast cancer in the laboratory may help doctors learn more about the effects of ritonavir on biomarkers involved in breast cancer growth. PURPOSE: This phase I/II trial is studying the best dose of ritonavir and its effects on biomarkers in women undergoing surgery for newly diagnosed breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Collaborator:
Susan G. Komen Breast Cancer Foundation
Treatments:
Ritonavir